ID   FM28
AC   CVCL_C583
SY   FM-28; FM 28
DR   cancercelllines; CVCL_C583
DR   Cosmic; 808545
DR   Cosmic; 972279
DR   Cosmic; 1047662
DR   Cosmic; 2163766
DR   ECACC; 13012412
DR   ESTDAB; ESTDAB-006
DR   GEO; GSM156041
DR   IARC_TP53; 26089
DR   Progenetix; CVCL_C583
DR   Wikidata; Q54835024
RX   PubMed=7656272;
RX   PubMed=8665567;
RX   PubMed=8968104;
RX   PubMed=9288767;
RX   PubMed=15592718;
RX   PubMed=17260012;
RX   PubMed=23851445;
CC   HLA typing: A*01,02; B*08,15 (PubMed=7656272).
CC   HLA typing: A*01:01,02:01; B*08:01,15:01:01:01; C*07:01:01,07:02; DPB1*04:01,01:01:01; DQB1*03:02,02:01; DRB1*04:01:01,03:01:01 (PubMed=15592718).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=17260012).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (PubMed=17260012; PubMed=23851445).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gln546Pro (c.1637A>C); ClinVar=VCV000375898; Zygosity=Unspecified (PubMed=23851445).
CC   Omics: Array-based CGH.
CC   Derived from site: Metastatic; Skin; UBERON=UBERON_0002097.
ST   Source(s): ECACC=13012412; ESTDAB=ESTDAB-006
ST   Amelogenin: X,Y
ST   CSF1PO: 13
ST   D13S317: 12
ST   D16S539: 11,13
ST   D3S1358: 15
ST   D5S818: 11,12
ST   D7S820: 10,14
ST   FGA: 22,24
ST   TH01: 6
ST   TPOX: 8 (ESTDAB=ESTDAB-006)
ST   TPOX: 9.3 (ECACC=13012412)
ST   vWA: 16,17
DI   NCIt; C3510; Cutaneous melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 02-05-24; Version: 23
//
RX   PubMed=7656272; DOI=10.1007/BF01527402;
RA   Kirkin A.F., Petersen T.R., Olsen A.C., Li L., thor Straten P.,
RA   Zeuthen J.;
RT   "Generation of human-melanoma-specific T lymphocyte clones defining
RT   novel cytolytic targets with panels of newly established melanoma cell
RT   lines.";
RL   Cancer Immunol. Immunother. 41:71-81(1995).
//
RX   PubMed=8665567; DOI=10.1007/s002620050272;
RA   Kirkin A.F., thor Straten P., Zeuthen J.;
RT   "Differential modulation by interferon gamma of the sensitivity of
RT   human melanoma cells to cytolytic T cell clones that recognize
RT   differentiation or progression antigens.";
RL   Cancer Immunol. Immunother. 42:203-212(1996).
//
RX   PubMed=8968104;
RA   Bartkova J., Lukas J., Guldberg P., Alsner J., Kirkin A.F.,
RA   Zeuthen J., Bartek J.;
RT   "The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently
RT   altered in melanoma pathogenesis.";
RL   Cancer Res. 56:5475-5483(1996).
//
RX   PubMed=9288767;
RA   Guldberg P., thor Straten P., Birck A., Ahrenkiel V., Kirkin A.F.,
RA   Zeuthen J.;
RT   "Disruption of the MMAC1/PTEN gene by deletion or mutation is a
RT   frequent event in malignant melanoma.";
RL   Cancer Res. 57:3660-3663(1997).
//
RX   PubMed=15592718; DOI=10.1007/s00262-004-0561-5;
RA   Rodriguez T., Mendez R., Roberts C.H., Ruiz-Cabello Osuna F., Dodi I.A.,
RA   Lopez-Nevot M.A., Paco L., Maleno I., Marsh S.G.E., Pawelec G.,
RA   Garrido F.;
RT   "High frequency of homozygosity of the HLA region in melanoma cell
RT   lines reveals a pattern compatible with extensive loss of
RT   heterozygosity.";
RL   Cancer Immunol. Immunother. 54:141-148(2005).
//
RX   PubMed=17260012; DOI=10.1038/sj.onc.1210252;
RA   Jonsson G., Dahl C., Staaf J., Sandberg T., Bendahl P.-O., Ringner M.,
RA   Guldberg P., Borg A.;
RT   "Genomic profiling of malignant melanoma using tiling-resolution
RT   arrayCGH.";
RL   Oncogene 26:4738-4748(2007).
//
RX   PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006;
RA   Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L.,
RA   Borg A., Pawelec G., Guldberg P.;
RT   "Mutual exclusivity analysis of genetic and epigenetic drivers in
RT   melanoma identifies a link between p14 ARF and RARbeta signaling.";
RL   Mol. Cancer Res. 11:1166-1178(2013).
//